Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Sanofi announces voluntary recall of Zantac products

1
SHARES

The pharmaceutical company Sanofi is voluntarily recalling its OTC Zantac products in the US and Canada due possible contamination with NDMA.

Sanofi has announced a voluntary recall of its Zantac (ranitidine) over-the-counter (OTC) products in the US and Canada. The move comes following the possible contamination of a nitrosamine impurity called N-nitrosodimethylamine (NDMA), a probable human carcinogen, in the medicine.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Due to inconsistencies in preliminary test results of the active ingredient used in the US and Canadian products, Sanofi has made its decision to recall the drugs.

According to the company, the ingredients used in its ranitidine products sold in the counties are sourced from different suppliers.

In a statement, Sanofi has said it is “committed to transparency and will continue to communicate results with health authorities from the ongoing testing and work with them to make informed decisions based on available data and evidence”.

MHRA announces recall of Zantac products made by GSK

The pharmaceutical company has also said it will decide on the level and extent of the recall after conferring with the US Food and Drug Administration (FDA) and Health Canada.  

The recall is the latest development in a series of recalls and testing recommendations for NDMA in ranitidine products. The European Medicines Agency (EMA) has also recently announced the update of its questions-and-answers document for marketing authorisation holders currently reviewing their products.

Share via
Share via